ImmuPharma plc (LON:IMM – Get Free Report)’s stock price dropped 6.3% during trading on Tuesday . The company traded as low as GBX 2.95 ($0.04) and last traded at GBX 2.95 ($0.04). Approximately 2,001,512 shares traded hands during trading, a decline of 90% from the average daily volume of 20,718,016 shares. The stock had previously closed at GBX 3.15 ($0.04).
ImmuPharma Price Performance
The company has a market cap of £12.28 million, a PE ratio of -295.00 and a beta of 1.53. The firm has a 50-day simple moving average of GBX 1.62 and a two-hundred day simple moving average of GBX 1.69.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Recommended Stories
- Five stocks we like better than ImmuPharma
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- The 3 Best Retail Stocks to Shop for in August
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- How to Find Undervalued Stocks
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
